.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
Colorcon
Medtronic
UBS
Covington
McKinsey
Cantor Fitzgerald
Federal Trade Commission
Citi

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,268,349

« Back to Dashboard

Which drugs does patent 8,268,349 protect, and when does it expire?


Patent 8,268,349 protects VIEKIRA XR, VIEKIRA PAK (COPACKAGED), KALETRA, NORVIR, and TECHNIVIE, and is included in five NDAs. There have been zero Paragraph IV challenges on Kaletra and Norvir

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-eight patent family members in twenty-five countries.

Summary for Patent: 8,268,349

Title:Solid pharmaceutical dosage form
Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50.degree. C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
Inventor(s): Rosenberg; Joerg (Ellerstadt, DE), Reinhold; Ulrich (Heidelberg, DE), Liepold; Bernd (Dossenheim, DE), Berndl; Gunther (Herxheim, DE), Breitenbach; Joerg (Mannheim, DE), Alani; Laman (Foster City, CA), Ghosh; Soumojeet (Gurnee, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:13/449,958
Patent Claim Types:
see list of patent claims
Dosage form; Formulation; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie IncVIEKIRA XRdasabuvir sodium; ombitasvir; paritaprevir; ritonavirTABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie IncVIEKIRA PAK (COPACKAGED)dasabuvir sodium ; ombitasvir; paritaprevir; ritonavirTABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
AbbvieKALETRAlopinavir; ritonavirTABLET;ORAL021906-002Nov 9, 2007RXYesNo► Subscribe► SubscribeY► Subscribe
AbbvieKALETRAlopinavir; ritonavirTABLET;ORAL021906-001Oct 28, 2005RXYesYes► Subscribe► SubscribeY► Subscribe
AbbvieNORVIRritonavirTABLET;ORAL022417-001Feb 10, 2010ABRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie IncTECHNIVIEombitasvir; paritaprevir; ritonavirTABLET;ORAL207931-001Jul 24, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,268,349

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,025,899Solid pharmaceutical dosage form► Subscribe
8,691,878Solid pharmaceutical dosage form► Subscribe
8,377,952Solid pharmaceutical dosage formulation► Subscribe
8,399,015Solid pharmaceutical dosage form► Subscribe
8,333,990Solid pharmaceutical dosage form► Subscribe
8,309,613Solid pharmaceutical dosage form► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,268,349

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Eurasian Patent Organization014446► Subscribe
Brazil122012031169► Subscribe
Canada2598827► Subscribe
Canada2821046► Subscribe
China101163479► Subscribe
Dominican RepublicP2006000050► Subscribe
Eurasian Patent Organization200701790► Subscribe
European Patent Office2206500► Subscribe
European Patent Office2283844► Subscribe
Georgia, Republic ofP20105083► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Julphar
Healthtrust
US Army
Colorcon
Baxter
Cantor Fitzgerald
Fish and Richardson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot